Aeglea BioTherapeutics Stock Forecast, Price & News

-0.09 (-1.38 %)
(As of 06/18/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume236,324 shs
Average Volume193,319 shs
Market Capitalization$315.71 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AGLE News and Ratings via Email

Sign-up to receive the latest news and ratings for Aeglea BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Aeglea BioTherapeutics logo

About Aeglea BioTherapeutics

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes cystinuria and research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.70 out of 5 stars

Medical Sector

323rd out of 2,097 stocks

Pharmaceutical Preparations Industry

150th out of 831 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Aeglea BioTherapeutics (NASDAQ:AGLE) Frequently Asked Questions

Is Aeglea BioTherapeutics a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aeglea BioTherapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Aeglea BioTherapeutics stock.
View analyst ratings for Aeglea BioTherapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Aeglea BioTherapeutics?

Wall Street analysts have given Aeglea BioTherapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aeglea BioTherapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Aeglea BioTherapeutics' next earnings date?

Aeglea BioTherapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Aeglea BioTherapeutics

How were Aeglea BioTherapeutics' earnings last quarter?

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) posted its earnings results on Sunday, May, 9th. The biotechnology company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by $0.11.
View Aeglea BioTherapeutics' earnings history

How has Aeglea BioTherapeutics' stock been impacted by Coronavirus?

Aeglea BioTherapeutics' stock was trading at $5.38 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AGLE stock has increased by 19.7% and is now trading at $6.44.
View which stocks have been most impacted by COVID-19

What price target have analysts set for AGLE?

3 equities research analysts have issued 12-month target prices for Aeglea BioTherapeutics' shares. Their forecasts range from $11.00 to $15.00. On average, they expect Aeglea BioTherapeutics' stock price to reach $13.00 in the next year. This suggests a possible upside of 101.9% from the stock's current price.
View analysts' price targets for Aeglea BioTherapeutics
or view top-rated stocks among Wall Street analysts.

Who are Aeglea BioTherapeutics' key executives?

Aeglea BioTherapeutics' management team includes the following people:
  • Dr. Anthony G. Quinn M.D., M.B Ch.B., Ph.D., FRCP, Pres, CEO, Principal Financial Officer & Director (Age 59, Pay $819.75k)
  • Dr. Leslie Sloan Ph.D., Chief Operating Officer (Age 50, Pay $538.35k)
  • Mr. Steven Weber, VP, Principal Accounting Officer & Corp. Controller (Age 44)
  • Joey Perrone, Sr. Director of Fin. & Investor Relations
  • Kelly Boothe Ph.D., Director of Corp. Communications
  • Mr. Eugene Sackett, VP of HR
  • Mr. Michael C. Hanley M.B.A., Chief Commercial Officer (Age 48)
  • Dr. Eric Bradford M.B.A., M.D., M.Sc., Chief Devel. Officer
  • Dr. Scott W. Rowlinson, VP of Research (Age 53)
  • Dr. F. Andrew Dorr, Exec. Officer (Age 68)

What is Anthony Quinn's approval rating as Aeglea BioTherapeutics' CEO?

3 employees have rated Aeglea BioTherapeutics CEO Anthony Quinn on Anthony Quinn has an approval rating of 100% among Aeglea BioTherapeutics' employees. This puts Anthony Quinn in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Aeglea BioTherapeutics' key competitors?

What other stocks do shareholders of Aeglea BioTherapeutics own?

When did Aeglea BioTherapeutics IPO?

(AGLE) raised $60 million in an IPO on Thursday, April 7th 2016. The company issued 3,500,000 shares at a price of $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Needham & Company was co-manager.

What is Aeglea BioTherapeutics' stock symbol?

Aeglea BioTherapeutics trades on the NASDAQ under the ticker symbol "AGLE."

Who are Aeglea BioTherapeutics' major shareholders?

Aeglea BioTherapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.83%), Nantahala Capital Management LLC (3.49%), Rock Springs Capital Management LP (3.22%), Point72 Asset Management L.P. (3.06%), Suvretta Capital Management LLC (2.79%) and Goldman Sachs Group Inc. (2.32%).
View institutional ownership trends for Aeglea BioTherapeutics

Which major investors are selling Aeglea BioTherapeutics stock?

AGLE stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Nantahala Capital Management LLC, Millennium Management LLC, Russell Investments Group Ltd., D. E. Shaw & Co. Inc., Renaissance Technologies LLC, Algert Global LLC, and Northern Trust Corp.
View insider buying and selling activity for Aeglea BioTherapeutics
or view top insider-selling stocks.

Which major investors are buying Aeglea BioTherapeutics stock?

AGLE stock was acquired by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Suvretta Capital Management LLC, Great Point Partners LLC, BlackRock Inc., Geode Capital Management LLC, Axiom Investment Management LLC, Axiom Investment Management LLC, and Dimensional Fund Advisors LP.
View insider buying and selling activity for Aeglea BioTherapeutics
or or view top insider-buying stocks.

How do I buy shares of Aeglea BioTherapeutics?

Shares of AGLE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aeglea BioTherapeutics' stock price today?

One share of AGLE stock can currently be purchased for approximately $6.44.

How much money does Aeglea BioTherapeutics make?

Aeglea BioTherapeutics has a market capitalization of $315.71 million and generates $3.89 million in revenue each year. The biotechnology company earns $-80,890,000.00 in net income (profit) each year or ($1.52) on an earnings per share basis.

How many employees does Aeglea BioTherapeutics have?

Aeglea BioTherapeutics employs 88 workers across the globe.

What is Aeglea BioTherapeutics' official website?

The official website for Aeglea BioTherapeutics is

Where are Aeglea BioTherapeutics' headquarters?

Aeglea BioTherapeutics is headquartered at 805 LAS CIMAS PARKWAY SUITE 100, AUSTIN TX, 78746.

How can I contact Aeglea BioTherapeutics?

Aeglea BioTherapeutics' mailing address is 805 LAS CIMAS PARKWAY SUITE 100, AUSTIN TX, 78746. The biotechnology company can be reached via phone at 512-942-2935 or via email at [email protected]

This page was last updated on 6/20/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.